FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
59.597,57 +4.678,00 (+8,52%)
Viridian Therapeutics, Inc. (0K1R.L)
| Chiusura precedente | 14,42 |
| Aperto | 15,29 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 15,29 - 15,48 |
| Intervallo di 52 settimane | 10,98 - 29,30 |
| Volume | |
| Media Volume | 682 |
| Capitalizzazione | 3,428M |
| Beta (5 anni mensile) | 1,10 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -5,14 |
| Prossima data utili | 08 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireViridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection of lead subcutaneous (SC) program in TED planned for year-end 2023 - - Company adds multiple senior executives to its leadership team, including its first Chief Commercial Officer, as part of its ongoing growth - - Conference call today at 4:30pm ET - WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a bi
- GlobeNewswire
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
- Partnership to support one of the Company’s preclinical programs outside of thyroid eye disease (TED) - WALTHAM, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25m
